A meta-analysis of 1312 HBsAg-negative and anti-HBc-positive lymphoma patients receiving rituximab-based chemotherapy reported a 9% HBV reactivation rate among those without prophylaxis [14]. This evidence concerns the gene KRT88P and lymphoma.